How Stratification Is Changing Trial Populations in Phase I
Introduction Phase I clinical trials have traditionally focused on enrolling healthy volunteers under tightly controlled inclusion and exclusion criteria. While this model has supported early safety and pharmacokinetic evaluation, it is increasingly insufficient for today’s targeted, biomarker-driven therapies. As drug development shifts toward precision medicine, stratification is becoming a core design element even at the […]
Biologics vs. Biosimilars: What Makes Their Clinical Evaluation Different?
Introduction Biologic medicines now represent one of the fastest growing segments of the global pharmaceutical market. Monoclonal antibodies, recombinant proteins, cell based therapies, and other large molecule products are transforming how diseases such as cancer, autoimmune disorders, and rare genetic conditions are treated. As patents expire on many of these therapies, biosimilars are entering development […]
How Novel Drug Delivery Systems Are Challenging Traditional BE Study Design
Bioequivalence (BE) studies have long relied on well-established assumptions about how drugs are administered, absorbed, and measured in the body. Traditional solid oral dosage forms such as tablets and capsules produce relatively predictable pharmacokinetic (PK) profiles that align well with conventional crossover BE designs and standard plasma sampling strategies. However, drug developers are increasingly moving […]
How Genetic Variability Is Being Accounted for in Bioequivalence and PK/PD Studies
As drug development becomes increasingly global, sponsors are paying closer attention to how genetic variability influences pharmacokinetics (PK), pharmacodynamics (PD), and bioequivalence (BE) outcomes. Differences in drug metabolism, transport, and receptor sensitivity across populations can meaningfully affect exposure profiles and therapeutic response. For BE and PK/PD studies in particular, these differences introduce both scientific complexity […]
The Role of Metabolomics and Biomarker Analysis in Early Phase Clinical Trials
The rise of metabolomics and biomarker analysis in early phase clinical trials is reshaping how development teams evaluate pharmacological activity, human variability, and early indicators of safety. For regulatory professionals, these tools present both opportunity and complexity. They offer stronger evidentiary support for early mechanistic understanding, yet they also introduce new demands around data interpretation, […]
Connecting Policy to CRO-Level Decisions in Bioequivalence Study Planning
Bioequivalence (BE) studies rely on a close connection between regulatory policy and the operational decisions made by CROs long before the first volunteer arrives on site. The success of a BE program depends on how well a CRO can interpret evolving guidance and translate it into protocol design, analytical preparation, statistical planning, recruitment strategies, and […]
How AI and Digital Monitoring Are Changing Clinical Trial Design in 2025
AI and digital monitoring have reached a turning point in 2025. After several years of incremental adoption, these tools are now reshaping how protocols are designed, how data is collected, and how sponsors think about feasibility and operational risk. The shift is not about replacing clinical teams. Instead, it is about elevating quality, accelerating insights, […]
What Sponsors Need to Know Before Their First-in-Human Trial
Launching a first-in-human (FIH) study marks one of the most critical milestones in a drug’s journey from discovery to development. It is the moment when preclinical promise meets clinical reality, and every decision made at this stage, scientific, operational, and regulatory, can shape the trajectory of the entire program. For sponsors embarking on their first […]
How the FDA’s 2025 Guidance Updates Are Reshaping Clinical Trials
The FDA’s 2025 draft guidance updates are set to change the way sponsors and their partners approach early-phase clinical development. For CROs, these updates aren’t just regulatory checkpoints, they represent new expectations around trial design, execution, and long-term planning. As sponsors seek CROs who can interpret, operationalize, and anticipate regulatory shifts, the ability to navigate […]
Why Data Entry Is the Backbone of Every Clinical Study
In clinical research, data is the backbone of every trial. Sponsors, regulators, and patients all depend on its accuracy to guide decisions about safety, efficacy, and approval. Yet one of the most critical steps in this process, data entry, is often underestimated as “just” administrative work. How data is entered, verified, and managed can make […]